Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04054284
Other study ID # JJStrossmayerU-1
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 1, 2019
Est. completion date February 12, 2020

Study information

Verified date February 2020
Source Josip Juraj Strossmayer University of Osijek
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Nearly 25% of the world's population relies on traditional medicinal systems but for professionals their effectiveness and even more safety are the main concern. Therefore, the aim of this preliminary study is to assess safety and effectiveness of herbal tea mixture on the control of glycaemia in Type 2 diabetics.The mixture consists of nine plants which have well-documented traditional use for the control of glycaemia.


Description:

The study will include Type 2 Diabetics who are taking only oral hypoglycemic medications (without insulin). Their therapy has to be stable for at least 3 months prior enrollment. Besides anthropometric measures, patient's glycaemia, renal and liver function will be monitored. Safety and adverse events will be closely monitored and these are the primary outcomes of the study. The main outcome measure of the effectiveness is HbA1c (glycated hemoglobin). Patients will be given detailed instructions on how to prepare the tea and the dosing. The intervention will last 3 months and during that time patients will be asked not to change their dietary or lifestyle habits.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date February 12, 2020
Est. primary completion date February 10, 2020
Accepts healthy volunteers No
Gender All
Age group 40 Years to 75 Years
Eligibility Inclusion Criteria:

- signed informed consent

- Croatian-speaking

- stable therapy for at least 3 months prior enrollment

- not taking any dietary supplements, especially herbal-based

- not taking any other herbal medicine (as a tea or a supplement)

- stable dietary and lifestyle patterns for at least 3 months prior enrollment

Exclusion Criteria:

- type 1 diabetes

- severe somatic disorder (oncological disease, hepatic, renal or autoimmune disease)

- pregnancy

- inability to fill in questionnaires in Croatian

- cognitive impairment

- psychiatric disorder

- undergoing current treatment for a major medical illness such as malignancy, autoimmune or immune deficiency disorder

- clotting disorders

- having nutritional deficiency (e.g. iron deficiency)

- current or history of eating disorder (anorexia, bulimia or EDNOS)

- current use of weight loss interventions (drugs; exercise interventions)

- regular use of dietary supplements, especially herbal-based

- regular use of herbal medicine (as a tea or a supplement)

- significant changes in diet or lifestyle patterns (e.g. increased physical activity) in the last 3 months prior the enrollment

Study Design


Intervention

Dietary Supplement:
Antidiabetic Herbal Tea
Patients will be instructed to take 250 mL of freshly prepared tea (1 tea spoon or 3 g of tea, pour over 250 mL of boiling water and leave aside for 15 min) 2 times per day during 12 weeks. The first tea needs to be taken in the morning prior any meal. The second can be taken at any time during the day but with at least 4 hour difference from the first cup.
Herbal Tea
Patients will be instructed to take 250 mL of freshly prepared tea (1 tea spoon or 3 g of tea, pour over 250 mL of boiling water and leave aside for 15 min) 2 times per day during 12 weeks. The first tea needs to be taken in the morning prior any meal. The second can be taken at any time during the day but with at least 4 hour difference from the first cup.

Locations

Country Name City State
Croatia Department of Food and Nutrition Research, Faculty of Food Technology Osijek
Croatia Health Centre Osijek Osijek
Croatia University Hospital Centre Osijek

Sponsors (3)

Lead Sponsor Collaborator
Josip Juraj Strossmayer University of Osijek Dom zdravlja Osijek (Health Centre Osijek), Osijek University Hospital

Country where clinical trial is conducted

Croatia, 

Outcome

Type Measure Description Time frame Safety issue
Other Creatinine Blood concentration of Creatinine (µmol) At enrollment (baseline) and at the end of the intervention (at 12 weeks).
Other Urea Blood concentration of Urea (mmol/L) At enrollment (baseline) and at the end of the intervention (at 12 weeks).
Other Total Proteins Blood concentration of Total Proteins (g/L) At enrollment (baseline) and at the end of the intervention (at 12 weeks).
Other Alanine transaminase Blood concentration of liver enzymes Alanine transaminase (ALT in U/L) At enrollment (baseline) and at the end of the intervention (at 12 weeks).
Other Aspartate transaminase Blood concentration of liver enzymes Aspartate transaminase (AST in U/L) At enrollment (baseline) and at the end of the intervention (at 12 weeks).
Other Alkaline phosphatase Blood concentration of liver enzymes Alkaline phosphatase (ALP in U/L) At enrollment (baseline) and at the end of the intervention (at 12 weeks).
Other Gamma-glutamyl transpeptidase Blood concentration of liver enzymes Gamma-glutamyl transpeptidase (GGT in U/L) At enrollment (baseline) and at the end of the intervention (at 12 weeks).
Other Body Weight Change in body weigh (in kg), Body Mass Index in kg/m2, waist circumference in cm At enrollment (baseline) and at the end of the intervention (at 12 weeks).
Other Body Mass Index Change in Body Mass Index (kg per square meter) At enrollment (baseline) and at the end of the intervention (at 12 weeks).
Other Waist Circumference Change in waist circumference (in cm) At enrollment (baseline) and at the end of the intervention (at 12 weeks).
Primary Number of patients with adverse event Adverse event (e.g. hypoglycaemia) reporting through direct contact researcher-patient. Starting from baseline, once per week until study completion at week 12.
Secondary Glycated Hemoglobin Blood HbA1c (%) At enrollment (baseline) and at the end of the intervention (at 12 weeks).
Secondary Fasting Glucose Blood Glucose (mmol/L) At enrollment (baseline) and at the end of the intervention (at 12 weeks).
See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Active, not recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes N/A